These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 20851283

  • 1. Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder.
    Muzyk AJ, Candeloro CL, Christopher EJ.
    Gen Hosp Psychiatry; 2010; 32(5):560.e1-3. PubMed ID: 20851283
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders.
    Centorrino F, Kelleher JP, Berry JM, Salvatore P, Eakin M, Fogarty KV, Fellman V, Baldessarini RJ.
    Am J Psychiatry; 2003 Jul; 160(7):1348-50. PubMed ID: 12832255
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacological issues in the treatment of bipolar disorder: focus on mood-stabilizing compounds.
    Potter WZ, Ketter TA.
    Can J Psychiatry; 1993 Apr; 38(3 Suppl 2):S51-6. PubMed ID: 8500079
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder.
    Winter HR, DeVane CL, Figueroa C, Ennis DJ, Hamer-Maansson JE, Davis PC, Smith MA.
    Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder.
    Schumock GT, Walton SM, Gupta SR, Cramer JA.
    Curr Med Res Opin; 2007 Aug; 23(8):1997-2004. PubMed ID: 17637202
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oxcarbazepine vs. valproate in the treatment of mood and schizoaffective disorders.
    Raja M, Azzoni A.
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):409-14. PubMed ID: 14604456
    [Abstract] [Full Text] [Related]

  • 15. A case of hyperammonemic encephalopathy after 11 years of valproate therapy.
    Stewart JT.
    J Clin Psychopharmacol; 2008 Jun; 28(3):361-2. PubMed ID: 18480705
    [No Abstract] [Full Text] [Related]

  • 16. Divalproex sodium in the treatment of adults with bipolar disorder.
    Davis LL, Williams R, Cates M.
    Expert Rev Neurother; 2004 May; 4(3):349-62. PubMed ID: 15853533
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders.
    Tohen M, Castillo J, Pope HG, Herbstein J.
    J Clin Psychopharmacol; 1994 Feb; 14(1):67-70. PubMed ID: 8151006
    [Abstract] [Full Text] [Related]

  • 19. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER?
    Reed RC, Dutta S.
    Ther Drug Monit; 2006 Jun; 28(3):413-8. PubMed ID: 16778728
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.